We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease (INPACT SFA I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01175850
Recruitment Status : Completed
First Posted : August 5, 2010
Results First Posted : October 6, 2015
Last Update Posted : May 16, 2017
Information provided by (Responsible Party):
Medtronic Endovascular

Brief Summary:
The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug coated) PTA balloons. The IN.PACT Admiral, besides the mechanical dilatation effect typical of all PTA balloons, releases a drug (paclitaxel) from the balloon surface into the vessel walls. This drug absorption is intended to limit the chances and the entity of artery re-narrowing over time.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease (PAD) Device: Drug-Coated Balloon (DCB) Device: PTA Balloon: Balloon Angioplasty Not Applicable

Detailed Description:

The efficacy of the IN.PACT Admiral balloon will be evaluated by assessing the primary patency rate of the treated arteries in the thighs of all patients included in the Study. Primary patency is a measure of the durability up to 1 year of the free lumen in the artery as restored during the procedure and is based on:

  • the need for re-dilatation of the previously treated vessel segment
  • an ultrasound examination The safety of the IN.PACT Admiral will be assessed by evaluating the incidence of deaths, amputations and re-dilatation of the pre-treated arteries in all patients included in the Study.

The IN.PACT SFA Trial enrolled in 2 phases: IN.PACT SFA I and IN.PACT SFA II. The 150-patient IN.PACT SFA I phase is intended to support the second phase IN.PACT SFA II IDE trial with congruent design and protocol. Aggregate data from the two phases is intended to provide statistical power for the 12-month primary safety and effectiveness endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 331 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
Study Start Date : September 2010
Actual Primary Completion Date : February 2014
Actual Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Medicines

Arm Intervention/treatment
Experimental: Drug-Coated Balloon (DCB)
IN.PACT Admiral: Balloon Angioplasty
Device: Drug-Coated Balloon (DCB)
balloon dilatation and provisional stenting with IN.PACT DCB

Active Comparator: Standard PTA
Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
Device: PTA Balloon: Balloon Angioplasty
balloon dilatation and provisional stenting with standard non-coated PTA balloon

Primary Outcome Measures :
  1. Primary Patency [ Time Frame: 12 Month ]
    Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) or restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) ≤ 2.4.

  2. Primary Safety Composite [ Time Frame: 12 month ]
    Primary safety composite is defined as freedom from death through 30 days or target limb major amputation or clinically-driven target vessel revascularization (CD-TVR) within 12 months post index procedure.

Secondary Outcome Measures :
  1. Major Adverse Events (MAE) Composite [ Time Frame: 12 month ]
    Major Adverse Events (MAE) composite defined as all-cause death, clinically-driven target vessel revascularization (CD-TVR), major target limb amputation, thrombosis at the target lesion site

  2. All-cause Death [ Time Frame: 12 month ]
  3. Target Vessel Revascularization (TVR) [ Time Frame: 12 month ]
  4. Target Lesion Revascularization (TLR) [ Time Frame: 12 month ]
  5. Time to First Clinically Driven Target Lesion Revascularization (CD-TLR) [ Time Frame: 12 month ]
    Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of ≥20% or >0.15 when compared to post-procedure baseline.

  6. Major Target Limb Amputation [ Time Frame: 12 month ]
  7. Thrombosis at the Target Lesion [ Time Frame: 12 month ]
  8. Primary Sustained Clinical Improvement [ Time Frame: 12 month ]
    Freedom from target limb amputation, target vessel revascularization (TVR), and increase in Rutherford class. Rutherford classification is a clinical staging system that is used to describe peripheral arterial disease.

  9. Secondary Sustained Clinical Improvement [ Time Frame: 12 month ]
    Freedom from target limb amputation and increase in Rutherford class.

  10. Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio (PSVR) >2.4). [ Time Frame: 12 month ]
    Duplex ultrasound measurement that measures the peak systolic velocity of blood (cm/sec) within a lesion divided by the peak velocity of blood (cm/sec) proximal to the lesion.

  11. Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio >3.4). [ Time Frame: 12 month ]
  12. Change From Baseline in Quality of Life Assessment by EuroQol Group 5-Dimension Self Report Questionnaire (EQ5D) at Month 12 [ Time Frame: Baseline to 12 month ]

    Quality of life assessment by EQ5D at 1 year compared to baseline. EQ5D is a standardised measure of health status and economic appraisal. The EQ5D consists of the EQ5D descriptive system which comprises the following variables for the 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. A complex algorithm that took individual dimensions and generated an overall score was used.

    EQ5D health state is used in the algorithm to calculate an overall score where - 0.109 = 'worst possible outcome' and 1.000 = 'best possible outcome'.

  13. Change From Baseline in Walking Capacity Assessment by Walking Impairment Questionnaire (WIQ) at 12 Months [ Time Frame: 12 month ]

    Walking capacity assessment by WIQ at 1 year compared to baseline. WIQ is a quality of life questionnaire that was specifically designed to assess the degree of impairment experienced by patients with claudication.

    Clinical outcomes were assessed by patients responses to question 1A. Question 1A is specific for calf or buttocks claudication and is used to create a summary score for analysis. Question 1A is expressed on a scale of 0% (unable to perform because of severe claudication) to 100% (no impairment).

  14. Device Success [ Time Frame: Day 1 ]
    Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below rated burst pressure (RBP).

  15. Procedural Success [ Time Frame: Day 1 ]
    Procedural success is defined as obtainment of ≤30% residual stenosis by visual estimate (with or without stenting)

  16. Clinical Success [ Time Frame: Day 1 ]
    Clinical success is defined as procedural success without procedural complications (death, stroke, major target limb amputation, thrombosis of the target lesion, or target vessel revascularization (TVR)) prior to discharge.

  17. Days of Hospitalization Due to the Index Lesion [ Time Frame: 12 month ]
    Days of hospitalization from procedure through 12 month.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

General Inclusion Criteria:

  • Age ≥18 years and ≤85 years
  • Patient or patient's legal representative is informed of the nature of the study, agrees to participate and has signed an EC approved consent form

Angiographic Inclusion Criteria:

- Target vessel is the superficial femoral artery and/or proximal popliteal artery (above the knee)

General Exclusion Criteria:

  • Patient unwilling or unlikely to comply with follow-up schedule
  • Stroke or STEMI within 3 months prior enrolment

Angiographic Exclusion Criteria:

- Acute or sub-acute thrombus in the target vessel

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01175850

Layout table for location information
Klinikum Rosenheim Institut für Diagnostische und Interventionelle Radiologie
Rosenheim, Pettenkoferstr, Germany, 83022
Sponsors and Collaborators
Medtronic Endovascular
Layout table for investigator information
Principal Investigator: Gunnar Tepe, Prof Dr. Med Klinikum Rosenheim
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Medtronic Endovascular
ClinicalTrials.gov Identifier: NCT01175850    
Other Study ID Numbers: P990
First Posted: August 5, 2010    Key Record Dates
Results First Posted: October 6, 2015
Last Update Posted: May 16, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases